Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Translational research patented first experimental treatment against idiopathic pulmonary fibrosis

Translational research patented first experimental treatment against idiopathic pulmonary fibrosis

December 26, 2007

Idiopathic pulmonary fibrosis is a disease with unknown cause with a very severe prognosis; when detected, it is already in an advanced stage. Patients suffering from it cannot develop with normality pulmonary gas exchange, and have a very reduced quality of life. Because of lack of an effective treatment, they rarely survive 5 years after being diagnosed. Idiopathic pulmonary fibrosis affects 13 out of 100,000 men and 7 out of 100,000 women, normally over 40 years of age. Researchers from the Biomedical Research Institute of Barcelona CSIC (IIBB-CSIC), a centre developing research in the framework of the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), have discovered and patented a method to stop and revert this disease in an animal model. A clinical study will be soon conducted in humans in the Hospital Clínic de Barcelona.

Results of their research work are published in the last issue of the American Journal of Respiratory and Critical Care Medicine (176(12):1261-8). This study has had the collaboration of basic researchers, such as Dr. Anna Serrano-Mollar, and Dr. Oriol Bulbena, first and last signatories of the study; and researchers with a clinical background, such as Dr. Antoni Xaubet, from the Unit of Pneumology of the Hospital Clínic de Barcelona. This turns this work into a paradigm of translational research promoted in IDIBAPS and through other initiatives such as the Network of Centres of Biomedical Research (CIBERs). This research work has been financed through a contribution from the Fondo de Investigaciones Sanitarias (FIS) from the Instituto de Salud Carlos III.




Gas exchange is developed in lungs thanks to type 1 pneumocytes in alveoli, cells recovering the inner walls of the alveolar cavity. Occupying the same spaces, there are also type II pneumocytes, precursor cells that repair the damaged alveolar tissue. When idiopathic pulmonary fibrosis appears, this regeneration process cannot be developed correctly and fibrosis advances until respiration is impossible. The technique developed by researchers from the IIBB-CSIC-IDIBAPS consists in a transplantation of type II pneumocytes via intratracheal. In order to monitor correctly the transplanted cells with genetic and fluorescence techniques, sexual chromosomal differences were used. Thus, the disease was induced in female rats, and cells from male rats were transplanted. This is a lowly invasive technique which has permitted to regenerate, for the first time, rat fibrotic alveoli where idiopathic pulmonary fibrosis was induced.

CSIC has patented as a treatment the cell suspension transplanted with this innovative strategy. The world patent will be proved in humans with a clinical study, soon conducted in the Hospital Clínic de Barcelona thanks to the financing of the Fundación Genoma España and CSIC This study will have the participation of 6 recently diagnosed patients who will receive a suspension of type II pneumocytes coming from a dead donor, since these cells cannot be cultured in the laboratory. All this events throw new and hopeful light into basic and clinical research lines. One of the following steps of researchers will be to try to obtain type II pneumocytes from adult stem cells.

IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer



Related Idiopathic Pulmonary Fibrosis Current Events and Idiopathic Pulmonary Fibrosis News Articles Idiopathic Pulmonary Fibrosis Current Events and Idiopathic Pulmonary Fibrosis News RSS Idiopathic Pulmonary Fibrosis Current Events and Idiopathic Pulmonary Fibrosis News RSS
Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients
The first findings from a one-of-a-kind, patient-driven effort to provide lung tissue for research might help doctors predict when patients with idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and also could point the way to interventions that could sustain them until life-saving transplants can be performed.

Protein may be strongest indicator of rare lung disease, study shows
Researchers at the University of Cincinnati (UC) have discovered a protein in the lungs that can help in determining progression of the rare lung disease Idiopathic Pulmonary Fibrosis (IPF).

Large clinical trial finds pirfenidone may help lung function in IPF patients
A large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.

UT Southwestern researchers identify gene linked to inherited form of fatal lung disease
Researchers at UT Southwestern Medical Center have determined that a mutation in a gene known for its role in defending the lungs against invading pathogens is responsible for some inherited cases of a lethal lung disease affecting older adults. The same mutation may also be associated with lung cancer, the researchers said.

Double threat: Deadly lung disease also linked to heart attacks
Patients with idiopathic pulmonary fibrosis (IPF) are three times as likely to experience severe coronary events-including heart attacks-than people without the disease.

Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in
Family, friends and neighbors remember Lisa Sandler Spaeth as an active mother of two in Potomac, Md., with a lot on the go, juggling her son's baseball games and her daughter's horseback-riding lessons with numerous committee obligations, organizing women's activities at her local synagogue.

Biomarkers identified for idiopathic pulmonary fibrosis
The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.

Rare Lung Disease Cells Indicate Higher Death Risk
Large numbers of certain cells in the lungs of patients diagnosed with idiopathic pulmonary fibrosis may increase their chance of death, UC researchers have discovered.

Smoking belies milder disease but worse prognosis for IPF patients
Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London.

Molecular pathway appears crucial in development of pulmonary fibrosis
A study led by Massachusetts General Hospital (MGH) researchers may have found a key mechanism underlying idiopathic pulmonary fibrosis (IPF), a usually fatal lung disease for which transplantation is the only successful treatment.
More Idiopathic Pulmonary Fibrosis Current Events and Idiopathic Pulmonary Fibrosis News Articles
The Official Patient's Sourcebook on Idiopathic Pulmonary Fibrosis

The Official Patient's Sourcebook on Idiopathic Pulmonary Fibrosis
by James N. Parker (Author)

This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to idiopathic pulmonary fibrosis (also alveolocapillary block; cryptogenic fibrosing alveolitis; diffuse fibrosing alveolitis; fibrosing alveolitis; Hamman-Rich syndrome; idiopathic diffuse interstitial pulmonary fibrosis), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various...

Idiopathic Pulmonary Fibrosis Medical Guide

Idiopathic Pulmonary Fibrosis Medical Guide
by Qontro Medical Guides (Author)

The Idiopathic Pulmonary Fibrosis Medical Guide is a publication which has been designed to better help readers understand Idiopathic Pulmonary Fibrosis. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis Medical Guide is highly recommended for those interested in understanding and learning more about Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis (Lung Biology in Health and Disease)

Idiopathic Pulmonary Fibrosis (Lung Biology in Health and Disease)
by Joseph P. Lynch III (Editor)

Key topics include the role of polymorphonuclear leukocytes in the pathogenesis of pulmonary fibrosis, and current treatment options, including medical therapy and lung transplantation.

  The Official Patient's Sourcebook on Idiopathic Pulmonary Fibrosis
by Icon Health Publications (Author)



  Idiopathic pulmonary fibrosis (Medical Grand Rounds)
by Galen B Toews (Author)



Pulmonary Arterial Hypertension and Interstitial Lung Diseases: A Clinical Guide

Pulmonary Arterial Hypertension and Interstitial Lung Diseases: A Clinical Guide
by Robert P. Baughman (Editor), Roberto G. Carbone (Editor), Giovanni Bottino (Editor)

Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 150 disorders characterized by scarring or fibrosis of the lungs. In Pulmonary Arterial Hypertension and Interstitial Lung Disease: A Clinical Guide, renowned experts provide a state-of-the-art overview of the problems seen by physicians in the clinical management of ILDs. Divided into two sections, the first part provides and update on general issues and introduces both interstitial lung disease and associated pulmonary hypertension. A detailed analysis of the pathology of the various interstitial lung diseases is also provided. The second part addresses specific categories of disease. Bronchiolitis, hypersensitivity pneumonitis, and other conditions are covered, and the use of inspiratory and...

© 2009 BrightSurf.com